Unlike general health products stocked in every health store, CJC-1295 reaches researchers through a dedicated online market that Ōmiya residents navigate through international suppliers. This online-only market structure is a genuine benefit for researchers — top vendors differentiate through analytical documentation in ways local stores never could. What consistently distinguishes top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. This guide takes Ōmiya researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Ōmiya researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Quality CJC-1295 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Suppliers that publish proactively are demonstrating research-grade standards. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. For Ōmiya researchers evaluating vendors with limited track records: a small initial order to verify quality before scaling up your order is the accepted approach among experienced researchers. For Ōmiya researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, begin with a small order, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Ōmiya
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the direct mitigation for this hazard. Researchers combining CJC-1295 with other compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
